503A or 503B? Who the HHS Peptide Policy Really Covers

Summary. The peptide compounding policy that the Department of Health and Human Services announced in the Federal Register on 30 October 2026 (FR Doc. 2026-22192, Docket HHS-OASH-2026-0496) is written for one part of the compounding system only. The notice says HHS does not intend to take enforcement action against a state-licensed pharmacy, a federal facility or a licensed physician compounding with one of the six peptide bulk drug substances in its Appendix A, which are the compounders that operate under section 503A of the Federal Food, Drug, and Cosmetic Act. Outsourcing facilities, which operate under section 503B, are not on that list. NPR reported on 28 October that the policy does not apply to 503B outsourcing facilities, and that one compounding company expects to make these products only at its smaller 503A site and only in small quantities. Our FDA Peptide Compounding Policy Tracker follows each step.

Research context (RUO). The two sections set different rules for bulk ingredients. According to FDA, a 503A compounder may use a bulk drug substance only if it complies with an applicable USP or National Formulary monograph, is a component of an FDA-approved drug product, or appears on the 503A bulks list; it must also come with a valid certificate of analysis from an FDA-registered establishment. A 503B outsourcing facility may use a bulk substance only if it is on a separate list of substances with a clinical need, or if the finished product is on FDA's drug shortage list. FDA's 503A page lists one final rule, from February 2019, that placed six substances on the 503A bulks list, plus a September 2019 proposal that would place five more on the list and not place 26 others; FDA says it will issue a final regulation after considering public comments. While the lists are built, FDA sorts nominated substances into Category 1, 2 or 3, and it says it does not intend to categorise substances nominated on or after 7 January 2025. The HHS policy does not add anything to the 503A bulks list and is not an FDA approval; HHS says FDA's future rulemaking may propose adding some or all of the six peptides. Comments on the docket are open on regulations.gov until 13 November 2026. For readers sorting out these terms, our Academy chapter on the state of the peptide market gives the wider context, and the COA page shows what a lot-level certificate contains. The policy concerns compounding for patients, not research-grade material.

This summary is for research-community awareness only and is not legal advice. For research use only. Not for human or veterinary use.